N-Ethyl-N,2-dimethyl-5-((2*R*,4*S*)-2-((((*R*)-1-(naphthalen-1-yl) ethyl)amino)methyl) chroman-4-yl)benzamide hydrochloride;

N,N-Diethyl-2-methyl-5-((2*R*,4*S*)-2-((((*R*)-1-(naphthalen-1-yl) ethyl) amino) methyl)chroman-4-yl)benzamide hydrochloride; and

(2-Methyl-5-((2*R*,4*S*)-2-((((*R*)-1-(naphthalen-1-yl)ethyl) amino)methyl)chroman-4-yl)phenyl)(pyrrolidin-1-yl)methanone hydrochloride;

or its pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising one or more compounds of Formula (I) according to claim 1, and one or more pharmaceutically acceptable excipients.

~~19. A method of treating, managing and/or lessening the diseases or disorders, syndromes or conditions associated with the modulation of calcium sensing receptor (CaSR) in a subject in need thereof wherein the method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.~~

~~20. The method of claim 19, wherein the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing receptor (CaSR) are selected from hyperparathyroidism, chronic renal failure (with or without dialysis), chronic kidney disease (with or without dialysis) and their complications.~~

~~21. The method of claim 20, wherein hyperparathyroidism is primary hyperparathyroidism, secondary hyperparathyroidism or tertiary hyperparathyroidism.~~

~~22. The method of claim 19, wherein the diseases, disorders, syndromes or conditions associated with the modulation of CaSR receptors are selected from the group consisting of parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, vascular & valvular calcification, abnormal calcium homeostasis, hypercalcemia, abnormal phosphorous homeostasis, hypophosphatemia, bone related diseases or complications arising due to hyperparathyroidism, chronic kidney disease or parathyroid carcinoma, bone loss post renal transplantation, osteitis fibrosa cystica, adynamic bone disease, renal bone diseases, cardiovascular complications arising due to hyperparathyroidism or chronic kidney disease, certain malignancies in which $(Ca^{2+})_e$ ions are abnormally high, cardiac, renal or intestinal dysfunctions, podocyte-related diseases, abnormal intestinal motility, diarrhea, augmenting gastrin or gastric acid secretion to directly or indirectly benefit in~~

~~atrophic gastritis or to improve absorption of pharmacological compounds, drugs or supplements from gastro-intestinal tract by augmenting gastric acidity.~~

~~23.~~ 19. A process for the preparation of compound of Formula (Ib):



(Ib)

wherein X, R, R_1, R_2, R_5 'm', 'n', 'p' and 'q' are as described in claim-1,

the process comprising the steps of:

a) oxidizing a compound of Formula (15) by using suitable oxidation agents to give compound of Formula (16) in suitable solvent(s);



(15) (16)

b) converting a compound of Formula (16) to compound of Formula (17) using $PhNTf_2$ (*N*-phenylbis(trifluoromethanesulfonimide) in presence of KHMDS (potassium hexamethyldisilazide);



(16) (17)

c) coupling of compound of Formula (17) with suitable aryl boronic acid or aryl boronic ester by following Suzuki coupling reaction to give compound of Formula (18) where Z is $-OR_6$ and R_6 is alkyl or benzyl;



(17) (18)

d) when Z is O-alkyl, then reducing the compound of Formula (18) with hydrogen over Palladium-Carbon to give ester compound of Formula (19) where Z is –O-alkyl;



e) converting the compound of Formula (19) obtained in step d) to the compound of Formula (Ia);



f) hydrolyzing the ester group in compound of Formula (Ia) to corresponding acid compound using suitable base and in suitable solvents;

g) converting the compound obtained in step f) to its hydrochloride salt having Formula (Ib);



h) when Z is O-benzyl in compound of Formula (18), then reducing the compound of Formula (18) with hydrogen over Palladium-Carbon to give acid compound of Formula (19) where Z is OH;



i) converting the compound of Formula (19) obtained in step h) to the compound of Formula (Ib);



~~24.~~ 20 A process for the preparation of compound of Formula (Id):



wherein X, R, R_1, R_2, R_5, R_7, R_c, R_d 'm', 'n', 'p', 'q' and 'r' are as described in claim 1, the process comprising the steps of:

a) coupling of acid compound of Formula (Ib) with suitable amines using suitable amide coupling reagents to give compound of Formula (Ic);



b) hydrolyzing the amido ester group, if the compound of Formula (Ic) is an ester, to corresponding acid compound of Formula (Id) using suitable reagent and solvents.



~~25.~~ 21. A compound which is 2, 6-Dimethyl-3-((2*R*, 4*S*)-2-((((*R*)-1-(naphthalen-1-yl) ethyl) amino) methyl) chroman-4-yl)benzoic acid hydrochloride.

~~26.~~ 22. A compound which is 2-Methyl-5-((2*R*,4*S*)-2-((((*R*)-1-(naphthalen-1-yl)ethyl)amino) methyl)chroman-4-yl)benzoic acid hydrochloride.

~~27.~~ 23. A compound which is 3-((2*R*,4*S*)-2-((((*R*)-1-(4-Fluoro-3-methoxyphenyl) ethyl) amino)methyl)chroman-4-yl)-5-methylbenzoic acid hydrochloride.

~~28.~~ 24. A compound which is 5-((2*R*,4 *S*)-2-((((*R*)-1-(4-Fluoronaphthalen-1-yl) ethyl) amino) methyl)chroman-4-yl)-2-methyl benzoic acid hydrochloride.

~~29.~~ 25. A compound which is 5-((2*S*,4*R*)-2-(2-(((*R*)-1-(4-Fluoro-3-methoxy phenyl) ethyl) amino) ethyl) chroman-4-yl)-2-methylbenzoic acid hydrochloride.